News stories about Heska Corporation (NASDAQ:HSKA) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Heska Corporation earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 50 out of 100, meaning that recent media coverage is somewhat likely to have an impact on the company’s share price in the near term.
Several research firms have recently commented on HSKA. Zacks Investment Research upgraded Heska Corporation from a “hold” rating to a “buy” rating and set a $101.00 price target on the stock in a report on Thursday, May 4th. B. Riley restated a “neutral” rating and issued a $83.00 price objective on shares of Heska Corporation in a report on Friday, April 28th. Finally, Aegis initiated coverage on shares of Heska Corporation in a report on Thursday, June 1st. They issued a “buy” rating and a $114.50 price objective on the stock. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $95.50.
Shares of Heska Corporation (HSKA) traded up 0.83% during midday trading on Wednesday, reaching $106.47. The company’s stock had a trading volume of 4,722 shares. The firm has a market capitalization of $757.64 million, a PE ratio of 57.03 and a beta of 0.81. The company’s 50-day moving average price is $96.38 and its 200 day moving average price is $89.94. Heska Corporation has a 1-year low of $41.22 and a 1-year high of $110.25.
Heska Corporation (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, May 2nd. The medical research company reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.37. Heska Corporation had a return on equity of 15.20% and a net margin of 10.45%. The company had revenue of $30.38 million during the quarter, compared to analysts’ expectations of $33.31 million. The company’s revenue was up 11.9% compared to the same quarter last year. On average, equities research analysts forecast that Heska Corporation will post $1.98 earnings per share for the current year.
In related news, EVP Steve Asakowicz sold 382 shares of Heska Corporation stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $100.08, for a total value of $38,230.56. Following the transaction, the executive vice president now directly owns 10,382 shares of the company’s stock, valued at $1,039,030.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Rod Lippincott sold 11,227 shares of the business’s stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $98.00, for a total transaction of $1,100,246.00. Following the completion of the sale, the executive vice president now directly owns 11,292 shares in the company, valued at approximately $1,106,616. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,265 shares of company stock valued at $2,983,439. 14.70% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This report was originally published by BBNS and is the property of of BBNS. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://baseballnewssource.com/markets/somewhat-positive-media-coverage-somewhat-likely-to-impact-heska-corporation-nasdaqhska-stock-price-updated/1115025.html.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with our FREE daily email newsletter.